PRospective Multiple Myeloma Impact Study

NCT02911571 · tracked via the Priya Life Science USA tracker

Sponsor

SkylineDx

Phase

Not applicable

Started

2018-02-27

Last updated

2026-04-28

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

MMprofiler SKY92 gene signature

MMprofiler SKY92 gene signature: MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 "high-risk" gene signature to aid in the determination of the Multiple Myeloma patient's prognosis

Study summary

This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Potentially multiple myeloma according to IMWG criteria * Candidates for systemic treatment Exclusion Criteria: * ECOG Performance Status \> 3 * Tumor sample that fails QA or QC criteria for MMprofiler

Primary outcome measure(s)

Change in treatment intention — Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler
Change in treatment intention will be assessed with a physician questionnaire pre- and post MMprofiler assessment

Trial sites (9)

Facility	City	Region
Lombardi Comprehensive Cancer Center	Washington D.C.	District of Columbia
Winship Cancer Institute, Emory University	Atlanta	Georgia
Hackensack University Medical Center	Hackensack	New Jersey
New York Presbyterian Brooklyn Methodist Hospital	Brooklyn	New York
Columbia University Medical Center	New York	New York
Weill Cornell Medicine	New York	New York
Levine Cancer Institute	Charlotte	North Carolina
Wake Forest Baptist Medical Center,	Winston-Salem	North Carolina
Medical College of Wisconsin	Milwaukee	Wisconsin

More SkylineDx trials in the USA

MElanoma Research Lymph Node Prediction Implementation National_001 Active, not recruiting

Other trials for the same condition

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma Recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma Active, not recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies Recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma Active, not recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02911571 on ClinicalTrials.gov ↗ ← All trials in the USA